Compliance Playbook for Comparing Video Conferencing Tools in Virtual Site Visits

Introduction: The Role of Video Conferencing in Remote Clinical Oversight

As decentralized and hybrid clinical trial models become standard, video conferencing tools have emerged as a primary mechanism for conducting virtual site visits. These tools are used to facilitate discussions between site personnel and monitors, perform remote source data verification (rSDV), and document interactions for inspection readiness. However, not all video conferencing platforms are built to meet regulatory expectations set by FDA, EMA, and ICH GCP guidelines.

In this compliance playbook, we compare commonly used video conferencing platforms in clinical research, identify their strengths and weaknesses from a regulatory standpoint, and offer guidance on documentation, validation, and CAPA practices related to virtual site visit technology.

Key Regulatory Expectations for Video Conferencing Tools

When used in clinical trial oversight, video conferencing tools must meet certain compliance benchmarks:

• 21 CFR Part 11 / Annex 11 Compliance: Tools should provide audit trails, electronic signatures, and validation documentation.
• Security: End-to-end encryption and HIPAA compliance for confidentiality.
• Access Controls: Role-based access for CRAs, investigators, and sponsor representatives.
• Documentation: Meeting logs, screen share audit trails, and inclusion in eTMF or QMS systems.
• Validation: Sponsors or CROs must validate the platform if it is used to influence trial decisions.

Platforms lacking these controls may be challenged during regulatory inspections, potentially leading to CAPA requirements or findings.

Comparison Table of Commonly Used Video Tools

The following table compares features of major video conferencing platforms often used in clinical trials:

Case Study: EMA Review of Video Tool Validation

In a multi-center European trial, a sponsor conducted all site initiation visits using Zoom. During EMA inspection, auditors requested validation evidence for Zoom’s platform, which the sponsor failed to provide. As a result, an observation was issued citing lack of system qualification.

The sponsor responded with a CAPA plan, transitioning future visits to Microsoft Teams with validation SOPs, user training records, and session logs uploaded to the eTMF.

Best Practices for Tool Selection and SOP Development

When selecting a video platform for virtual visits, sponsors and CROs should follow a standardized approach that includes:

• System Qualification: Conduct formal validation for any tool that influences trial data or decision-making.
• Vendor Assessment: Perform audits or due diligence on third-party vendors providing conferencing solutions.
• SOP Development: Create SOPs that cover meeting initiation, screen-sharing protocols, and documentation requirements.
• Data Integrity Controls: Ensure session recordings, shared screens, and chat transcripts are saved or summarized.
• eTMF Archival: Upload visit summaries, agendas, and training documentation to the eTMF or equivalent system.

Managing CAPA for Video Tool Failures

When video platform issues disrupt trial oversight or site communication, the resulting deviations must be captured in the monitoring log or deviation tracker. Common issues include:

• Session disconnection mid-review
• Unauthorized recording by a site user
• Unavailability of audit trails
• Failure to verify site screen-sharing controls

Each of these should be linked to a root cause analysis and followed by CAPA documentation. Corrective measures may include transitioning to a validated tool or retraining users on SOP-compliant video use.

Regulatory Guidance and External Resources

Agencies have not published platform-specific rules, but expect that sponsors demonstrate how oversight is maintained. The following resources offer insight:

• NIHR Guidance on Remote Monitoring and Communication Tools
• FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency
• ICH E6(R3) Draft – Section on Digital Health Tools

Checklist for Inspection-Ready Video Conferencing Use

The following checklist can help ensure compliance during sponsor QA audits or regulatory inspections:

• Validated conferencing platform in use
• SOP for video-based visits available and version controlled
• Site and CRA training documented
• Logs of all sessions with timestamps and participant list
• Summaries of discussions, shared documents captured in CRA visit report
• eTMF contains all relevant artifacts

Conclusion: Choose Compliance Over Convenience

While ease of use is important, video conferencing tools must be selected based on regulatory suitability, validation capability, and security. With increasing reliance on virtual models, sponsors must elevate their video platform strategy from an IT decision to a core compliance priority. SOPs, training, CAPA planning, and inspection readiness must align to create a seamless and audit-proof virtual site visit experience.

How to Conduct Virtual Site Visits with a CAPA-Driven Approach

Introduction: Virtual Site Visits and Regulatory Expectations

The evolution of decentralized clinical trials and remote monitoring practices has brought virtual site visits to the forefront of regulatory oversight strategies. Both sponsors and clinical sites must now demonstrate compliance with Good Clinical Practice (GCP) while conducting remote visits that meet the expectations of authorities like the FDA, EMA, and ICH.

Unlike traditional on-site visits, virtual site visits introduce new challenges related to technology, security, documentation, and real-time communication. Consequently, implementing a Corrective and Preventive Action (CAPA) framework during these visits becomes essential to ensure issues are managed systematically and future risks are mitigated.

This tutorial outlines the key steps for conducting a virtual site visit using a structured CAPA framework and highlights regulatory expectations along with real-world examples.

Step-by-Step Process for Virtual Site Visits

Virtual site visits can be categorized into various types—site qualification, initiation, monitoring, and closeout. Regardless of visit type, a standardized process must be followed to ensure regulatory compliance and audit readiness. Below is a structured walkthrough of the process.

Step 1: Pre-Visit Planning and Risk Assessment

Pre-visit planning involves risk-based decision-making to identify which sites require virtual visits, the focus of the visit, and anticipated challenges. Sponsors typically develop a Virtual Site Visit Plan (VSVP) as a formal document.

Key Elements of the VSVP include:

• Purpose and scope of the visit
• Technology platforms to be used (e.g., Zoom, Microsoft Teams, Veeva)
• Roles and responsibilities
• Schedule of sessions with key personnel
• Data access permissions and audit trail enablement
• Confidentiality and security provisions

Use of remote monitoring platforms must comply with EU Clinical Trial Regulation 536/2014 and 21 CFR Part 11 standards for data integrity.

Step 2: Site Readiness and Pre-Qualification

Prior to the visit, the site must complete a Virtual Visit Readiness Checklist that includes:

• Hardware and internet speed checks
• Availability of staff and key personnel
• Testing of screen sharing and document access tools
• Confirmation of data de-identification (if applicable)
• Backup plan in case of connectivity failures

A dummy table of readiness status can be maintained:

Step 3: Conducting the Visit – Real-Time Execution

During the actual virtual site visit, the following activities must be documented:

• Review of regulatory documents (e.g., 1572, IRB approvals, CVs)
• Live review of electronic source documents (eSource)
• Verification of informed consent process
• Interviewing site staff regarding protocol adherence
• Observing drug storage areas via live video
• Monitoring AE/SAE documentation handling

The virtual visit should be recorded (if permitted), and notes must be entered into a Virtual Visit Log filed in the TMF.

Step 4: CAPA Identification During and After the Visit

Any deficiencies observed during the virtual site visit should be captured and evaluated through a CAPA process. CAPA identification must include:

• Clear description of issue (e.g., missing PI signature on lab report)
• Risk assessment (e.g., High – Subject Safety Impact)
• Root cause analysis (RCA) – using 5 Whys or Fishbone diagram
• Immediate correction (e.g., obtain signature, retrain staff)
• Preventive actions (e.g., system alerts, SOP revision)

Example CAPA record:

Step 5: Post-Visit Documentation and TMF Filing

All virtual visit documents must be archived appropriately in the TMF (Trial Master File). Key documents include:

• Virtual Site Visit Plan
• Readiness checklist and screenshots
• Virtual Site Visit Log
• CAPA tracking sheet
• Correspondence emails
• Audit trail exports

Filing should follow the DIA TMF Reference Model and be traceable for inspectors.

Best Practices and Common Pitfalls

Lessons learned from industry case studies reveal some best practices and pitfalls:

Best Practices:

• Conduct dry runs prior to scheduled visit
• Use dual monitors for simultaneous document review
• Assign a dedicated tech support liaison
• Log all time-stamped notes into the eTMF

Common Pitfalls:

• Relying on unsecured file-sharing platforms
• Failing to test video tools under firewall restrictions
• Skipping root cause analysis for minor issues
• Neglecting real-time documentation during the visit

Conclusion: Integrating CAPA into Virtual Oversight

Virtual site visits are no longer optional—they are a regulatory reality. However, their success hinges on a CAPA-driven framework that goes beyond operational execution. Sponsors must integrate proactive issue identification, structured correction, and long-term prevention into each virtual oversight activity.

By following the steps outlined in this guide, sponsors and CROs can improve both the effectiveness and defensibility of virtual site visits. More importantly, they can demonstrate to regulators that quality systems are evolving alongside technology.